Welcome, Guest. Please login or register.
April 17, 2024, 03:30:42 pm

Login with username, password and session length

  • Total Members: 6307
  • Latest: golfer
  • Total Posts: 55125
  • Total Topics: 4851
  • Online Today: 57
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 42
Total: 42


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Poll: 75% of Primary Care Docs Unaware of New Hep C Meds  (Read 6974 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Poll: 75% of Primary Care Docs Unaware of New Hep C Meds
« on: July 25, 2014, 10:45:30 am »
About two-thirds of 150 polled PCPs in a recent study did not know that Janssen’s Olysio (simeprevir) and Gilead Sciences’ Sovaldi (sofosbuvir) received FDA approval in 2013. A little less than one in three of the physicians were even familiar with the first-generation hep C protease inhibitors, Incivek (telaprevir) and Victrelis (boceprevir), despite the fact that they have been on the market for almost three years.

Read more... http://www.hepmag.com/articles/primary_care_2501_25793.shtml

Offline rainbowray

  • Member
  • Posts: 263
  • Gen 1B
Re: Poll: 75% of Primary Care Docs Unaware of New Hep C Meds
« Reply #1 on: July 25, 2014, 10:57:39 am »
Not surprised at all.


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.